The following study was recently activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.
Protocol Title: BA3182: An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma
PI: Lawrence Feldman, MD, part of the Cancer Center’s Translational Oncology Research Program
Sponsor: NovoCure Ltd.
Protocol Title: ALLO-647-201 : A Randomized, Open-label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic Car T Cell Therapy
PI: Carlos Galvez, MD, UI Health Division of Hematology and Oncology
Sponsor: Allogene Therapeutics